UK Biotech

UK bank launches £2.5B plan to fund innovation, with a special place for its long-ailing biotech scene

Can a government-owned bank loaded with cash help trigger a biotech boom in the UK?

We’ll find out.

The British Business Bank has just unveiled a £2.5 billion scheme to invest in “innovative” companies in the UK, and they have a special focus on drug discovery and development.

The BBB is transferring £400 million over to the newly created British Patient Capital to get things going. And they’re starting with a small, £9 million investment in the Dementia Discovery Fund, which is backing life sciences companies in the field. Another £30 million goes to Draper Esprit’s £115 million capital raise.

The idea here is that the government can inspire investments totaling three times their £2.5 billion investment. 

The UK’s Golden Triangle is home to some of the world’s best known scientists, and has a major backer with AstraZeneca and GSK based in the country. But there’s also a strong underlying belief that the country lacks the kind of experienced execs and financial support for the hub to break out of its limited boundaries.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->